TY - JOUR

T1 - Radiotherapy and theranostics

T2 - a Lancet Oncology Commission

AU - Abdel-Wahab, May

AU - Giammarile, Francesco

AU - Carrara, Mauro

AU - Paez, Diana

AU - Hricak, Hedvig

AU - Ayati, Nayyereh

AU - Li, Jing Jing

AU - Mueller, Malina

AU - Aggarwal, Ajay

AU - Al-Ibraheem, Akram

AU - Alkhatib, Sondos

AU - Atun, Rifat

AU - Bello, Abubakar

AU - Berger, Daniel

AU - Delgado Bolton, Roberto C

AU - Buatti, John M

AU - Burt, Graeme

AU - Bjelac, Olivera Ciraj

AU - Cordero-Mendez, Lisbeth

AU - Dosanjh, Manjit

AU - Eichler, Thomas

AU - Fidarova, Elena

AU - Gondhowiardjo, Soehartati

AU - Gospodarowicz, Mary

AU - Grover, Surbhi

AU - Hande, Varsha

AU - Harsdorf-Enderndorf, Ekaterina

AU - Herrmann, Ken

AU - Hofman, Michael S

AU - Holmberg, Ola

AU - Jaffray, David

AU - Knoll, Peter

AU - Kunikowska, Jolanta

AU - Lewis, Jason S

AU - Lievens, Yolande

AU - Mikhail-Lette, Miriam

AU - Ostwald, Dennis

AU - Palta, Jatinder R

AU - Peristeris, Platon

AU - Rosa, Arthur A

AU - Salem, Soha Ahmed

AU - Dos Santos, Marcos A

AU - Sathekge, Mike M

AU - Shrivastava, Shyam Kishore

AU - Titovich, Egor

AU - Urbain, Jean-Luc

AU - Vanderpuye, Verna

AU - Wahl, Richard L

AU - Yu, Jennifer S

AU - Zaghloul, Mohamed Saad

AU - Zhu, Hongcheng

AU - Scott, Andrew M

PY - 2024/11/30

Y1 - 2024/11/30

N2 - Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of radiotherapy to date and to address the important issue of access to the promising field of theranostics at a global level. A marked disparity in the availability of radiotherapy machines between high-income countries and low-income and middle-income countries (LMICs) has been identified previously and remains a major problem. The availability of a suitably trained and credentialled workforce has also been highlighted as a major limiting factor to effective implementation of radiotherapy, particularly in LMICs. We investigated initiatives that could mitigate these issues in radiotherapy, such as extended treatment hours, hypofractionation protocols, and new technologies. The broad implementation of hypofractionation techniques compared with conventional radiotherapy in prostate cancer and breast cancer was projected to provide radiotherapy for an additional 2·2 million patients (0·8 million patients with prostate cancer and 1·4 million patients with breast cancer) with existing resources, highlighting the importance of implementing new technologies in LMICs. A global survey undertaken for this Commission revealed that use of radiopharmaceutical therapy-other than 131I-was highly variable in high-income countries and LMICs, with supply chains, workforces, and regulatory issues affecting access and availability. The capacity for radioisotope production was highlighted as a key issue, and training and credentialling of health professionals involved in theranostics is required to ensure equitable access and availability for patient treatment. New initiatives-such as the International Atomic Energy Agency's Rays of Hope programme-and interest by international development banks in investing in radiotherapy should be supported by health-care systems and governments, and extended to accelerate the momentum generated by recognising global disparities in access to radiotherapy. In this Commission, we propose actions and investments that could enhance access to radiotherapy and theranostics worldwide, particularly in LMICs, to realise health and economic benefits and reduce the burden of cancer by accessing these treatments.

AB - Following on from the 2015 Lancet Oncology Commission on expanding global access to radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created to assess the access and availability of radiotherapy to date and to address the important issue of access to the promising field of theranostics at a global level. A marked disparity in the availability of radiotherapy machines between high-income countries and low-income and middle-income countries (LMICs) has been identified previously and remains a major problem. The availability of a suitably trained and credentialled workforce has also been highlighted as a major limiting factor to effective implementation of radiotherapy, particularly in LMICs. We investigated initiatives that could mitigate these issues in radiotherapy, such as extended treatment hours, hypofractionation protocols, and new technologies. The broad implementation of hypofractionation techniques compared with conventional radiotherapy in prostate cancer and breast cancer was projected to provide radiotherapy for an additional 2·2 million patients (0·8 million patients with prostate cancer and 1·4 million patients with breast cancer) with existing resources, highlighting the importance of implementing new technologies in LMICs. A global survey undertaken for this Commission revealed that use of radiopharmaceutical therapy-other than 131I-was highly variable in high-income countries and LMICs, with supply chains, workforces, and regulatory issues affecting access and availability. The capacity for radioisotope production was highlighted as a key issue, and training and credentialling of health professionals involved in theranostics is required to ensure equitable access and availability for patient treatment. New initiatives-such as the International Atomic Energy Agency's Rays of Hope programme-and interest by international development banks in investing in radiotherapy should be supported by health-care systems and governments, and extended to accelerate the momentum generated by recognising global disparities in access to radiotherapy. In this Commission, we propose actions and investments that could enhance access to radiotherapy and theranostics worldwide, particularly in LMICs, to realise health and economic benefits and reduce the burden of cancer by accessing these treatments.

U2 - 10.1016/S1470-2045(24)00407-8

DO - 10.1016/S1470-2045(24)00407-8

M3 - Review article

C2 - 39362232

VL - 25

SP - e545-e580

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 11

ER -